FDA Grants Arrowhead's Plozasiran Entry into STAR Pilot Program

Key Facts

1Arrowhead Pharmaceuticals announced that the FDA granted plozasiran entry into the Split Real Time Application Review (STAR) pilot program.

Arrowhead Pharmaceuticals announced that the FDA granted plozasiran entry into the Split Real Time Application Review (STAR) pilot program. The company said in a statement via Business Wire that the program is designed to expedite the review process for supplemental new drug applications for treatments addressing serious conditions.

The drug is intended to treat severe hypertriglyceridemia (sHTG), a condition that increases the risk of acute pancreatitis. ARWR closed at $61.54 on October 6, 2026, after reaching a session high of $63.19 and a low of $60.56.